Today I am pleased to announce the brand new Save Our Bones Bulletin, which will now replace the Latest Osteoporosis News series.
The Save Our Bones Bulletin is an in-depth analysis of what’s making headlines in the osteoporosis and osteopenia world.
Keeping Savers informed on the most recent bone health news is part of my unwavering commitment to the community.
In today’s Save Our Bones Bulletin, you’ll read about a new experimental implant that delivers electric currents to muscles, aiming to increase bone density.
I’ve also uncovered some sneaky (and despicable) tactics by Big Pharma and the Medical Establishment that hope to keep you in the dark while they profit from their deception.
And last but not least, I bring you a study that conclusively nixes a previous deceptive and much-touted “benefit” of bisphosphonates.
From Merck’s new pill that destroys bones to the twisting of data about bisphosphonates, I’m glad to shine the light on just what’s happening out there in the mainstream.
Let’s get started with the latest headlines!
New Implant Builds Bone By Causing Muscle Contractions
In order to study the action of muscle on deteriorating bone, scientists in Liverpool, England inserted a tiny device into the leg muscles of rats. This implant stimulated the muscles with a mild electric current, causing a brief, painless contraction every 30 seconds.
The bones that were attached to these muscles actually increased in density by double digits.
“When muscles are repeatedly activated like this, it seems to boost the growth of new bone in the surrounding area.
Exactly how stimulating muscles makes fragile bones stronger is unclear. One theory is that the repeated contractions draws stem cells into the area – these then develop into new bone.
The experimental new implant could be a solution because doctors would be able to implant it in parts of the body where bones are crumbling, such as the hip or spine.
The results, published in the Proceedings of the Royal Society, showed that after just one month, bone volume had increased by 30 per cent.” 1
While this proposed implant is not a toxic drug, I am dubious. For one thing, the article claims it’s unclear “how stimulating muscles makes fragile bones stronger.” Actually, it’s quite clear.
It’s a known fact that the action of muscle on bone increases bone density. This is known as Wolff’s Law, and I based the Densercise™ Epidensity Training System on this very concept. Why undergo a potentially dangerous procedure to stimulate your muscles, when you can simply enjoy regular exercise?
Like the the idea of taking a pill to simulate the benefits of exercise, this implant is another attempt to circumnavigate the “trouble” of motion. And in so doing, you’ll also forfeit all the benefits of exercise which go beyond bone density, such as increased energy, improved mood, and better weight management and cardiovascular health.
And finally, should this implant ever make the list of “approved” devices, there could be some bad long-term side effects. It’s impossible to predict what complications this device could produce.
Nothing can take the place of regular bone-building exercises!
Merck’s New Insomnia Drug Receives FDA Approval… But It Can Destroy Your Bones
Ironically, Merck, the manufacturers of Fosamax, have been granted FDA approval for a brand-new insomnia drug, Belsomra…but an odd side effect is that it can undermine the formation of new bone.
“The U.S. Food and Drug Administration said on Wednesday it has approved a new insomnia drug made by Merck & Co.
The drug, to be called Belsomra, is the first in a new class of sedatives that block chemicals in the brain called orexins that help keep people awake.
The FDA recommended that Belsomra be listed as a controlled substance because it can be addictive and has the potential to be abused.”2
Orexins are proteins, and nerve cells use them to communicate with one another. They also play a dualistic role in bone formation – orexins block the formation of new bone, but they also promote it. This is how they work:
Orexins interact with 2 different receptors: OX1R and OX2R. The first one lowers ghrelin levels (the “hunger hormone”), and the second receptor reduces the hormone leptin, which decreases bone mass.
Scientists at UT Southwestern Medical Center teamed up with researchers in Japan to study this process in mice. They found that mice that lacked both receptors had very weak and fragile bones. In contrast, mice with high levels of orexins had greater numbers of osteoblasts and therefore superior bone formation.3
Now let’s put this all together. As the article says, Belsomra works by blocking orexins. But the science clearly shows that low orexin activity leads to low bone density and fragile bones.
Savers know that getting plenty of quality sleep is essential for bone health. But the bone health benefits will be undermined with Belsomra, which will weaken bones during sleep.
Fortunately, Savers avoid prescription drugs. But as part of my commitment to the community, I want to keep you informed of Big Pharma’s tactics and schemes. For example, you’ll notice the potentially addictive nature of Belsomra – another indication that Big Pharma and the FDA may have other motives beyond helping the the public get a good night’s sleep.
More Bad News For Bisphosphonates: They Do Not Reduce Breast Cancer Risk
In the face of mounting evidence against the safety and effectiveness of the most widely-prescribed class of osteoporosis drugs, the Medical Establishment has tried (and continues to try) every possible effort to redeem bisphosphonates.
As part of this campaign to find something good about drugs such as Boniva, Fosamax, Reclast, Actonel, etc., the Medical Establishment claimed that bisphosphonates prevent breast cancer.
But it turns out that, once again, the Medical Establishment is presenting misleading “evidence”…
“A new analysis of clinical trial data by a researcher team at the University of California, San Francisco suggests that earlier evidence linking use of osteoporosis drugs and successful breast cancer prevention was misleading.
According to the researchers, assessment of several observational studies showing that women who took Fosamax and Reclast/Zometa were less likely to develop breast cancer may actually be due to another factor – low estrogen.
Known as bisphosphonates, Fosamax and Reclast/Zometa are drugs given to osteoporotic patients. In 2011, the drugs were given to women undergoing treatment for breast cancer as a standard of care. A previous study reported that Reclast/Zometa lowered the risk of death from breast cancer in women by 37 percent after taking the drug at six-month intervals for three years. A connection between low estrogen and treatment with Zometa in breast cancer patients was also made in the study. A 2009 study also indicated that Fosamax along with other bone drugs may cut the risk of breast cancer in older women.
Now however, the UCSF researchers reported that administering the osteoporosis drugs did not protect the women from developing breast cancer. Low estrogen levels, which weakens bones, already protects women from most forms of breast cancer and therefore lowered osteoporotic women’s risk of developing breast cancer.
‘They may have seen a lower risk of breast cancer in women using bisphosphonates in the earlier observational studies because those women had a lower risk of breast cancer to begin with,’ said Dr. Trisha Hue, lead author of the study.”4
I don’t expect Mainstream Medicine to give up on their effort to find something “positive” about bisphosphonates; these drugs are just too lucrative. Frankly, I find it appalling that Big Pharma and the Medical Establishment continue to twist information so as to mislead the public regarding their products.
The bottom line is that no drug is completely safe. And drugs do not cure or treat disease anyway; they merely mask symptoms. Plus there’s always a price to pay; sometimes, a very steep price.
The Osteoporosis Reversal Program takes a completely different approach. With its emphasis on nutrition, diet, and exercise, the Program shows you exactly how to balance your body pH, which sets the stage for strong and healthy bones.
The Program addresses the whole person from the inside out, and doesn’t merely focus on artificially manipulating a singular biological function such as bone remodeling.
That’s Where Your Save Our Bones Health Coach Comes In
I know that you may have questions or concerns on your journey to healthier bones. That’s why, when you purchase the Osteoporosis Reversal Program, you’ll have unlimited private email access to your own personal Save Our Bones Health Coach, a caring, knowledgeable team member who can answer your questions about osteoporosis drugs, nutrition, or just simply offer you some encouragement.
Here are some benefits of having your own Save Our Bones Health Coach:
- Provides a “personal touch” to your bone health journey.
- Offers encouragement and affirmation in your decision to manage your osteoporosis without drugs.
- Coaches are personally trained by me and knowledgeable about the Program, so you’ll receive reliable, consistent information.
So if you’re ready to rebuild your bones and would like someone to come alongside you for inspiration and information, then if you haven’t yet, I invite you to check out the Osteoporosis Reversal Program today.
1 Hagan, Pat. “Muscle twitcher that strengthens crumbly bones: Tiny implant could revolutionise the treatment of osteoporosis.” UK Daily Mail Online. 18 August 2014. Web. http://www.dailymail.co.uk/health/article-2728291/Muscle-twitcher-strengthens-crumbly-bones.html
2 “FDA approves new insomnia drug.” Foxnews.com. 14 August 2014. Web. http://www.foxnews.com/health/2014/08/14/fda-approves-new-insomnia-drug/?intcmp=obnetwork
3 Wei Wei, Toshiyuki Motoike, et al. “Orexin Regulates Bone Remodeling via a Dominant Positive Central Action and a Subordinate Negative Peripheral Action.” Cell Metabolism, 2014; 19 (6): 927 DOI: 10.1016/j.cmet.2014.03.016
4 Masangkay, Estel Grace. “Evidence Of Osteoporosis Drugs’ Breast Cancer Prevention ‘Misleading’.” Pharmaceutical Online. 14 August, 2014. Web. http://www.pharmaceuticalonline.com/doc/evidence-of-osteoporosis-drugs-breast-cancer-prevention-misleading-0001